Recent Finacing
Recent Raise
Aegle Therapeutics develops mesenchymal stem-cell–derived extracellular vesicle therapies, including AGLE-102, targeting dystrophic epidermolysis bullosa and other severe dermatological conditions, operating from Arlington and Miami.
